<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239849</url>
  </required_header>
  <id_info>
    <org_study_id>SKimlipid</org_study_id>
    <nct_id>NCT01239849</nct_id>
  </id_info>
  <brief_title>Korean AMADEUS Study</brief_title>
  <official_title>A Multicenter, Eight Weeks Treatment, Single Step Titration, Open Label Study Assessing the Percentage of Korean Diabetic Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Dose 10mg, 20mg, 40mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because Diabetes Mellitus is one of the major risk factors for CV disease and lots of related
      evidences have been published including CARDS study that showed definite benefit of statin
      treatment in DM patients and influenced ADA guideline. &amp; NCEP ATP III update. However, there
      are large unmet medical needs for DM patients who don't reach their target LDL-C level
      defined NCEPT ATP III update because of physicians usually start with the lowest dose of
      statin and then titrate to the goal. Thus, we are curious about changing our prescription
      pattern into more tailored way; selecting starting dose based on the individual risk factors
      and concomitant status will impact the goal achieving rate for DM patients. Besides that, we
      are going to find out preliminary data about other markers change; small dense LDL and
      adiponectine;. Small dense LDL-C is more inflammatory and atherogenic LDL-C that may explain
      the impact of triglyceride. Adiponectin is another good marker related with obesity and
      metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects in the total LDL cholesterol group achieving their LDL cholesterol target after 8 weeks of treatment.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Percentage of subjects in the total LDL cholesterol group achieving their LDL cholesterol target after 4 weeks of treatment.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Change and percent change from baseline to 4 and 8 weeks of treatment for LDL cholesterol, HDL cholesterol, non-HDL cholesterol, LDL cholesterol/HDL cholesterol ratio, Total cholesterol, Triglyceride subjects in the total group.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Percentage of subjects who achieved LDL cholesterol target with no titration of atorvastatin and after one step titration of atorvastatin</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Change and percent change from baseline to 4 and 8 weeks of treatment for small dense LDL cholesterol, adiponectin, hs-CRP</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Safety of atorvastatin through laboratory assessment, physical examination, vital signs, and adverse events.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diabetes Mellitus, Hypercholessterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin, 10mg, 20mg, 40mg</intervention_name>
    <description>If initial LDL cholesterol between 100~ 129mg/dl then starting dose of Atorvastatin is 10mg, 130~159 mg/dl is 20 mg, 160~220mg/dl is 40mg.
After 4weeks treatment, if LDL cholesterol is below 100mg/dl then continue starting dose and if not reach below 100mg/dl then titration double dose.
After 4 weeks treatment, recheck the LDL cholesterol</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Korean Diabetes Patients

          2. Is ≥ 18 and ≤ 80 years olds

          3. Has diagnosis of dyslipidemia

          4. Has 100 mg/dl ≤ LDL cholesterol ≤ 220 mg/dl

          5. Has triglyceride level ≤ 600 mg/dl

          6. Has HbA1c ≤ 12%

          7. If female, is postmenopausal, surgically sterilized, or using a reliable methods of
             birth control considered suitable by the investigator

          8. Can discontinue all current antilipidemic medication for the 4 week washout period

          9. Has provided written informed consent prior to the initiation of any study procedure

        Exclusion Criteria:

          1. Is pregnant or lactating

          2. Abuse alcohol and/or any other drug

          3. Uncontrolled diabetes ( HbA1c &gt; 12% )

          4. Has impaired hepatic function, as shown by but not limited to alanine aminotransferase
             (ALT,SGOT) or aspartate aminotransferase (AST, SGOT) ≥ 2times the upper limit of
             normal at baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SUNG RAE KIM, A. Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucheon St. Mary Hospital, The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SUNG RAE KIM, A. Professor</last_name>
    <phone>+82-32-340-2025</phone>
    <email>kimsungrae@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sung Rae Kim</name>
      <address>
        <city>Bucheon</city>
        <state>Kyeongki</state>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SUNG RAE KIM, A. Professor</last_name>
      <phone>+82-32-340-2025</phone>
      <email>kimsungrae@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>JAE HYUNG CHO, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>KI HO SONG, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SEUNG JUN OH, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>HYE SOON KIM, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>KYUNG MOOK CHOI, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>IN JOO KIM, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SOO KYOUNG KIM, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SUNG HEE CHOI, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>JONG WHA KIM, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>CHAN HEE JUNG, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MIN KYOUNG MOON, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>HYE JIN KIM, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>YOUNG IL KIM, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>KANG SEO PARK, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>DONG JOON KIM, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SANG YOUNG KIM, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>CHANG BUM LEE, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <last_update_submitted>November 12, 2010</last_update_submitted>
  <last_update_submitted_qc>November 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bucheon St Mary Hospital</name_title>
    <organization>The Catholic University of Korea</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus, Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

